Horus Pharma’s DMLA Market Entry and Therapeutic Innovations

Horus Pharma is entering the market for age-related macular degeneration (AMD) with the launch of a biosimilar treatment. According to reports from Le Journal des Entreprises and Santé Magazine, the company is targeting a condition that remains the primary cause of visual impairment for adults over the age of 50.

The move signals a strategic expansion for the pharmaceutical firm into a high-demand therapeutic area. Santé Magazine describes the biosimilar as a promising development for patients managing the disease.

What is the role of the new Horus Pharma biosimilar?

A biosimilar is a biological product that is highly similar to an already approved reference medicine, according to general pharmaceutical standards. In the context of AMD, these treatments typically target the proteins that cause abnormal blood vessel growth in the retina.

Le Journal des Entreprises identifies the AMD market as a strategic priority for Horus Pharma. By introducing a biosimilar, the company provides an alternative to existing biologics, which often carry high costs for healthcare systems and patients.

Medical context for this development involves the treatment of “wet” AMD. This form of the disease involves the growth of leaky blood vessels under the macula, the part of the eye responsible for sharp, central vision. Anti-VEGF (vascular endothelial growth factor) therapies are the standard of care to stop this leakage, and biosimilars of these therapies aim to maintain efficacy while reducing costs.

When will the new AMD study begin in Lyon?

A new study dedicated to AMD is scheduled to launch in Lyon in 2027, according to Le Progrès. The study arrives as the region seeks to address the impact of the disease on the aging population.

Le Progrès reports that AMD is the leading cause of visual handicap for individuals over 50. This demographic shift increases the necessity for localized clinical research and expanded access to treatments in urban centers like Lyon.

How are other innovations changing AMD treatment?

While Horus Pharma focuses on biosimilars, other technological shifts are occurring. Breizh-info.com reports that AMD is currently at the dawn of a therapeutic revolution, citing three distinct paths of innovation:

• Biosimilars: Lower-cost versions of existing biological therapies.
• Gene Therapy: Treatments designed to allow the eye to produce its own medicine, potentially reducing the need for frequent injections.
• Bionic Eyes: Implantable devices intended to restore some level of vision to those with advanced retinal degeneration.

Le Figaro Santé notes that two specific innovations in the field could transform the daily lives of patients. These developments aim to move beyond simple symptom management toward more sustainable vision preservation.

The contrast between these approaches is significant. Biosimilars, like the one from Horus Pharma, focus on increasing the accessibility of current gold-standard care. In contrast, gene therapy and bionic eyes represent a shift toward curative or restorative interventions for patients who no longer respond to traditional injections.

Why does the timing of these developments matter?

The proliferation of AMD treatments is a response to an aging global population. Because the disease primarily affects those over 50, the volume of patients requiring long-term, expensive injections has placed a strain on public health budgets.

The introduction of biosimilars is a recognized method for increasing patient access. When multiple companies produce similar biological drugs, competition typically lowers the price of the reference product and the biosimilar alike.

However, the long-term outlook depends on the success of the more radical therapies mentioned by Breizh-info.com. If gene therapy becomes widely available, it could eliminate the need for the monthly or bi-monthly clinic visits currently required for anti-VEGF biosimilars.

For now, the 2027 Lyon study and the Horus Pharma entry represent a dual approach: improving the delivery of existing medical science while preparing for the next generation of ocular interventions.